How OPSYNVI® Works to Help You Take on PAH

OPSYNVI® is a once-daily approach to two foundational pathways—helping you treat PAH by targeting the nitric oxide and endothelin pathways.

Active Ingredients

OPSYNVI® is a medicine that contains 2 medicines called macitentan and tadalafil and is used for long-term treatment of adults with pulmonary arterial hypertension (PAH), which is high blood pressure in the arteries of your lungs.

About Macitentan
About Tadalafil

Review the Medication Guide for a complete list of ingredients in OPSYNVI®.

Clipboard and ribbon with check marks

Combination therapy with macitentan and tadalafil is a clinical guideline* recommendation for PAH treatment.

Clinical guidelines are evidence-based recommendations that assist healthcare providers in diagnosing and treating a medical condition.

Dual combination treatment with macitentan and tadalafil, is a guideline recommendation for the initial treatment of pulmonary arterial hypertension (PAH) for patients with certain types of PAH who do not have other conditions of the heart and lungs.

*2022 European Society of Cardiology/European Respiratory Society Guidelines.

Cause unknown (idiopathic), heritable, drug-related PAH, or PAH linked to connective tissue disease.

Stay in the Know With OPSYNVI®

Exciting updates are underway! Sign up for exclusive updates on OPSYNVI®.

Sign Up
No footer links content fetched